TYVASO®

Hold Company

UNITED THERAP

Learn More

Dosage and Administration

SOLUTION;INHALATION

Specification

0.6MG/ML

Indication

TYVASO® is used to treat pulmonary arterial hypertension and pulmonary hypertension associated with ILD.

Use

Instructions for Use

API

TREPROSTINIL

API Structure

We Supply

TREPROSTINIL

Note:

null

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
10376525	2027/5/14
10716793	2027/5/14
11723887	2028/12/15
9339507	2028/3/10
9358240	2028/5/5
9593066	2028/12/15
9604901	2028/12/15

API Patent

Patent No	Expiration Date
9593066	2028/12/15
9604901	2028/12/15

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.